Pharmacokinetics of cyclosporine as a function of energy-protein deficiency in children with chronic renal failure

Journal of Clinical Pharmacology

Volumn 37, Issue 3, 1997, Pages 179-185

  Lares Asseff, Ismael ^a,b   Zaltzman, Samuel ^a   Pérez Guillé, María Gabriela ^a   Camacho, Guadalupe A ^a   Murguía, Teresa ^a   López, María Del Carmen ^a   Toledo, Alejandra R ^a   Zaltzman Rudy, Amy B ^a   Cravioto, Joaquín ^b  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADOLESCENT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MALNUTRITION; ORAL DRUG ADMINISTRATION; PROTEIN DEFICIENCY; SCHOOL CHILD;

EID: 0030939645     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04779.x     Document Type: Article

References (46)

1. Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schröter GPJ: Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 1981;305:266-269.
2. Reitz BA, Bieber CP, Raney AA, Pennock JL, Jamieson SW, Dyer PE, Stinson EB: Orthotopic heart and combined heart and lung transplantation with cyclosporin A immune suppression. Transplant Proc 1981;13:393-396.
3. Powels RL, Clink H, Cloane J, Barret AJ, Kay HEM, McElwain TJ: Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet 1978:ii:1327-1331.
4. Nussenblatt RB, Palestine AG, Chan CC: Cyclosporin A therapy in the treatment of intraocular inflammatory disease, resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983;96:275-282.
5. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al: Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110-3116.
6. Bougneres PF, Carel JC, Castano L, Boitard G, Gardin JP, Landais P, et al: Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318:663-670.
7. Førre O, Bjerkhoel F, Salvesen CF, Berg KJ, Rugstad HE, Saelid G, et al: An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 1987;30:88-92.
8. Tejani A, Butt K, Khawar MR, Suthanthiran M, Rosenthal CJ, Tratchman H, et al: Cyclosporine (CY) induced remission of relapsing nephrotic syndrome (RNS) in children (abstract). Kidney Int 1986;29:206.
9. Palestine AG, Nussenblatt RB, Chan CC: Side effects of systemic: cyclosporine in patients not undergoing transplantation. Am J Med 1984;77:652-656.
10. Radeke HH, Christians U, Bleck JS, Sewing KF, Resch K: Additive and synergistic effects of cyclosporine metabolites on glomerular mesangial cells. Kidney Int 1991;39:1255-1266.
11. Kahan BD, Grevel J: Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988;46:631-644.
12. Kahan BD: Cyclosporine. N Engl J Med 1989;321:1725-1738.
13. Clardy CHW, Schroeder TJ, Myre SA, Wadhwa NK, Pesce AJ, First MR, et al: Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic, and bone-marrow transplants. Clin Chem 1988;34:2012-2015.
14. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993;24:472-495.
15. Hoppu K, Koskimies O, Holmberg CH, Hirvisalo EL: Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol 1991;5:1-4.
16. Maurer G: Metabolism of cyclosporine. Transplant Proc 1985;17(suppl):19-26.
17. Kronbach T, Fischer V, Meyer VA: Cyclosporine metabolism in human liver: identification of a cytochrome P-450 III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-635.
18. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P: Metabolism of cyclosporine A; IV: purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporine A oxidase) as a product of P-450 3A gene subfamily. Drug Metab Dispos 1989;17:197-207.
19. Walter-Jack Y, Klotz U: Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996;1:47-64.
20. Feinstein EI, Kopple JD: Severe wasting and malnutrition in a patient undergoing maintenance dialysis. Am J Nephrol 1985;5:389-405.
21. Feinstein EI: Parenteral nutrition in acute renal failure. Am J Nephrol 1985;5:145-149.
22. Richard P: Protein metabolism in uremia. Nephron 1975; 14:134-152.
23. Holliday MA: Calorie deficiency in children with uremia: Effect upon growth. Pediatrics 1972;50:590-597.
24. Chantler C, Holliday MA: Growth in children with renal disease with particular reference to the effects of calorie malnutrition: A review. Clin Nephrol 1973;1:228.
25. Wadhwa NK, Schroeder TJ, Pesce AJ, Myre SA, Clardy CHW, First MR: Cyclosporine drug interactions: a review. Ther Drug Monit 1987;9:399.
26. Waterlow JC: Classification and definition of protein-calorie malnutrition. BMJ 1972;3:566-569.
27. Ramos Galván R: Somatometría pediátrica. Estudio semilongitudinal en niños de la Ciudad de México. Arch Invest Med Méx 1975;6(suppl 1):83-96.
28. Gibbons S, Grevel J, Reynolds M, Ried M, Rutzky LP Kahan BD: Comparison and correlation of assays for monitoring cyclosporine drug levels in renal transplant recipients. Transplant Proc 1988;20:339-344.
29. Gibaldi M, Perrier D: Pharmacokinetics. Second Edition. New York: Marcell Dekker, 1982;445-449.
30. Dixon WJ, Brown MB: Derivative-free nonlinear regression. In: BMDP-79. (Biomedical Computer Program P-series). Los Angeles: University of California Press, 1979;484-498.
31. Akaike H: A bayesian analysis of the minimum AIC procedure. Am Inst Statist Math 1978;30:9-14.
32. Brown RD, Manno JE: ESTRIP, a basic: computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 1978;67:1687-1691.
33. Gibaldi M: Biopharmaceutics and Clinical Pharmacokinetics. Fourth Edition. Malvern, PA: Lea & Febiger, 1991;14-23.
34. BMDP-79. (Biomedical Computer Program P-Series). Los Angeles: University of California Press, 1979.
35. Waterlow JC, Alleyne GA: Protein malnutrition in children: Advances in knowledge in the last ten years. Adv Protein Chem 1971;25:117-241.
36. Stickler GB, Bergen BJ: A review: Short stature in renal disease. Pediatr Res 1973;7:978-982.
37. West CD, Smith WC: An attempt to elucidate the cause of growth retardation in renal disease. Am J Dis Child 1956;91:460-476.
38. Coles JA: Body composition in chronic renal failure. Q J Med 1972;41:25-47.
39. Roche AF: Growth assessment in abnormal children. Kidney Int 1978;14:369-377.
40. Castilla L, Cravioto J, Pérez B: Patterns of muscle and fat mass repair during recovery from advanced infantile protein energy malnutrition. Eur J Clin Nutr (in press).
41. Yee GC, Lennon TP, Gmur DJ, Cheney CL, Oeser D: Effect of obesity on CSA disposition. Transplantation 1988;45:649-651.
42. Flechner SM, Kolbeinsson ME, Tam J, Lum B: The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation 1989;47:806-810.
43. Mraz W, Zink RA, Graf A, Preis D, Illner WD, Land W, et al: Distribution and transfer of CSA among the various human lipoprotein classes. Transplant Proc 1983;15:2426.
44. Lithell H, Odlind B, Selinus I, Lindberg A, Lindstrom B, Frödin L: Is the plasma lipoprotein pattern of importance for treatment with cyclosporine? Transplant Proc 1986;18:50-51.
45. Nestle M: Nutrition in Clinical Practice. Greenbrae, CA: Jones Medical Publications, 1985.
46. Zöllner N: Feststellung des Ernährungszustandes, In, Kühn HA, Zöllner N (eds.): Allgemeine and Klinische Ernährungslehre. Bd II, Teil I. Stutgart: Georg Thieme Verlag, 1978;1-7.